Automated Insulin Delivery

The AJMC® Automated Insulin Delivery compendium is a comprehensive resource for clinical news and expert insights for this technology, which has revolutionized diabetes care.

Omnipod 5 May Improve Psychosocial Outcomes for Patients With T1D, Study Suggests

July 21st 2022, 5:55pm


Patients with type 1 diabetes (T1D) who used the Omnipod 5 Automated Insulin Delivery (AID) System saw significant improvements in psychosocial outcomes, including diabetes distress and hypoglycemic confidence over a 3-month period.

Omnipod 5 Effective at Glycemic Control Across Spectrum of Insulin Needs

July 6th 2022, 5:48pm


Knowing that insulin requirements vary widely among persons who have type 1 diabetes, 3-month effectiveness of the Omnipod 5 Automated Insulin Delivery System was evaluated across 6 daily insulin doses.

Omnipod 5 T1D Glycemic Outcomes Continue to Improve Over the Longer Term

June 29th 2022, 7:46pm


Extended safety and effectiveness of the Omnipod 5 AID system were investigated in this 12-month extension of a previous 3-month study conducted among persons living with type 1 diabetes (T1D).

There Is More to Blame Than Tech for T1D Outcomes Disparities, Investigators Argue

June 21st 2022, 7:24pm


Investigators from the Pediatric Diabetes Center at Hassenfeld Children’s Hospital at NYU Langone investigated outcomes disparities as they related to diabetes technology use among youth living with type 1 diabetes (T1D).

Artificial Intelligence “Twin” Technology Improves Remission Rates for T2D

June 12th 2022, 11:30am


A wearable device powered by artificial intelligence and the Internet of Things to create a "digital twin" reduced glycated hemoglobin and improved remission rates for patients with type 2 diabetes (T2D) through personalized care.

CREATE Trial Data Add to Support of Open-Source AID Use in T1D

June 9th 2022, 12:41pm


Findings presented at the 82nd Scientific Sessions of the American Diabetes Association support the safety and efficacy of open-source automated insulin delivery (AID) systems among children and adults living with type 1 diabetes (T1D).

Fully Artificial Pancreas Produces Results Comparable With Hybrid Artificial Pancreas

May 31st 2022, 2:40pm


This new study from Canada compared outcomes in patients living with type 1 diabetes who used 2 closed-loop insulin delivery systems: a fully artificial pancreas that did not require meal input and a hybrid artificial pancreas that required carbohydrate counting.

Emotional Improvement Seen Among T1D Patients Using CLC Systems

May 24th 2022, 2:39pm


The authors of this study evaluated outcomes among children aged 7 to 16 years, all living with type 1 diabetes (T1D), who attended a 3-day virtual education camp that focused on their use of a closed-loop control (CLC) system for insulin delivery.

Stronger Frameworks Needed to Implement CGM Use at Hospital Discharge

May 20th 2022, 5:08pm


Continuous glucose monitor (CGM) use as part of a telemedicine program in patients with type 2 diabetes transitioning out of a hospital setting and to a different diabetes therapy was evaluated in this new open-label study.

Superior T1D Control Seen With HCL Systems vs SAP Therapy in Older Adults

May 15th 2022, 8:13pm


Type 1 diabetes (T1D) can be especially difficult to manage in older adults, so this new multinational review compared the safety and effectiveness of a hybrid closed-loop (HCL) system and sensor-augmented pump (SAP) therapy.